Mark R. Philips, M.D.

Mark R. Philips, M.D.

NYU Grossman School of Medicine

Mark R. Philips, M.D. is Professor of Medicine, Cell Biology and Biochemistry & Molecular Pharmacology at NYU Grossman School of Medicine. Dr. Philips earned his B.A. from Harvard and his M.D. from Columbia before training in internal medicine and rheumatology at New York University Bellevue Hospital. He is a physician-scientist who has focused on the post-translational modification and membrane targeting of RAS and related GTPases. He has run an NIH-funded molecular cell biology laboratory for 30 years. Among his contributions to the field are the characterization of ICMT, the enzyme that methyl esterifies RAS and other CAAX proteins, the discovery of the indirect trafficking of RAS GTPases to the plasma membrane via the endomembrane system, compartmentalized signaling of RAS revealed by fluorescent probes, phosphorylation of KRAS4B and direct regulation of hexokinase by KRAS4A. Dr. Philips is a Fellow of the American Society for the Advancement of Science, a member of the American Society for Clinical Investigation and the Association of American Physicians and he recently received an NCI Outstanding Investigator Award. He also serves as the Director of the NYU Medical Scientist Training Program and Associate Director for Education of the NYU Perlmutter Cancer Center.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb